Sun Pharmaceutical Industries Ltd. Share Price, Target, and Technical View

Sun Pharmaceutical Industries Ltd., commonly known as Sun Pharma, is one of India’s largest pharmaceutical companies and ranks among the top global generic drug manufacturers.

With a broad product portfolio that includes a wide range of generic medications, specialty drugs, and over-the-counter products, Sun Pharma has become a significant player in the global pharmaceutical market.

In this article, we’ll explore Sun Pharma’s share price, target projections, and technical analysis to guide investors in making well-informed decisions.

Overview of Sun Pharma

Attribute	Details
Market Capitalization	₹2,10,000+ Crore (as of 2024)
Industry	Pharmaceuticals
Primary Products	Generic Drugs, Specialty Pharmaceuticals, Active Pharmaceutical Ingredients (APIs)
NSE Symbol	SUNPHARMA
BSE Code	524715

Current Share Price and Historical Performance

Current Share Price

The share price of Sun Pharma reflects a blend of industry trends, company performance, and regulatory developments. As of 2024, Sun Pharma is trading between ₹1,100 and ₹1,150 on the NSE and BSE. Due to fluctuations in the pharmaceutical sector, the share price may vary, so checking real-time data is essential for investors.

Check the Latest Price: Sun Pharma Share Price – NSE India | Sun Pharma Share Price – BSE India

Historical Performance

Sun Pharma’s stock has shown resilience and growth due to its expansion into specialty drugs, acquisitions, and growing market presence in the US and emerging markets. Below is an analysis of Sun Pharma’s share price growth over recent years:

Year	Share Price Start (₹)	Share Price End (₹)	Annual Growth (%)
2020	490	590	20.4%
2021	590	690	16.9%
2022	690	830	20.3%
2023	830	1,100	32.5%
2024 (YTD)	1,100	1,150	4.5%

Dividend Yield and Consistency

Sun Pharma has a history of paying dividends, which adds stability for investors looking for returns in addition to capital appreciation.

Year	Dividend per Share (₹)	Dividend Yield (%)
2020	3.5	0.6%
2021	4.0	0.6%
2022	5.0	0.7%
2023	5.5	0.7%
2024	6.0	0.8%

Share Price Target for Sun Pharma

Analysts often provide price targets based on Sun Pharma’s performance, market trends, and the potential impact of new drug launches or regulatory changes. Below are some target price projections:

Analyst	2024 Target Price (₹)	2025 Target Price (₹)	Investment Outlook
Motilal Oswal	1,200	1,320	Positive
HDFC Securities	1,180	1,250	Positive
ICICI Direct	1,250	1,350	Positive
Kotak Securities	1,180	1,260	Neutral
Morgan Stanley	1,220	1,350	Positive

Note: Targets may change based on market conditions, regulatory shifts, and company performance updates.

Fundamental Analysis of Sun Pharma

Revenue and Earnings Growth

Sun Pharma’s revenue and profit growth are driven by its global reach, focus on specialty drugs, and strategic acquisitions. Below is an overview of its financial performance over the past three years:

Metric	FY 2022 (₹ Crore)	FY 2023 (₹ Crore)	FY 2024 (₹ Crore)
Revenue	40,000	46,000	51,200
Operating Profit	12,000	14,300	16,200
Net Profit	6,500	8,100	9,200
Earnings per Share	27.5	34.2	39.3

Valuation Ratios

The valuation ratios of Sun Pharma offer insights into the stock’s pricing relative to its earnings and book value.

Ratio	FY 2023	FY 2024
Price-to-Earnings (P/E)	29.5x	28.3x
Price-to-Book (P/B)	4.1x	4.0x
Dividend Yield	0.8%	0.8%

Technical Analysis of Sun Pharma

Key Technical Indicators

Technical analysis of Sun Pharma reveals trends in its share price, which can assist in determining future movements based on patterns and indicators.

Indicator	Current Value	Signal
50-Day Moving Average	₹1,140	Neutral
200-Day Moving Average	₹1,080	Bullish
Relative Strength Index (RSI)	60	Neutral
MACD	Positive	Bullish
Bollinger Bands	Narrow Uptrend	Bullish

Trend Analysis

• Short-Term: Sun Pharma is trading above its 200-day moving average, which indicates positive sentiment. Short-term indicators such as MACD and RSI show a bullish trend.
• Medium-Term: Consistent support levels and an uptrend in specialty drugs make Sun Pharma a stock with medium-term potential. The RSI at 60 suggests that while momentum is present, the stock isn’t overbought.

Support and Resistance Levels

Level	Price (₹)
Immediate Support	1,080
Next Support	1,050
Immediate Resistance	1,150
Next Resistance	1,200

Market Sentiment and Analyst Recommendations

Market sentiment around Sun Pharma remains optimistic, with its expansion into specialty drugs and growth in the US market. The following ratings offer insights from prominent brokerage firms:

Recent Analyst Ratings

• Motilal Oswal: Buy (Target ₹1,200)
• HDFC Securities: Buy (Target ₹1,180)
• ICICI Direct: Buy (Target ₹1,250)
• Morgan Stanley: Buy (Target ₹1,220)

Is Sun Pharma a Good Investment?

Pros of Investing in Sun Pharma

1. Global Presence: Sun Pharma’s international footprint, especially in the US, makes it a strong player in the global pharmaceutical market.
2. Innovative Drug Pipeline: With a focus on specialty and innovative drugs, Sun Pharma is positioned for growth in both domestic and international markets.
3. Consistent Dividend Payout: Sun Pharma’s dividend payouts make it attractive for income-focused investors.
4. Resilient Financials: Despite challenges, Sun Pharma has maintained strong financial health, ensuring long-term stability.

Cons of Investing in Sun Pharma

1. Regulatory Risks: As with all pharmaceutical companies, regulatory changes and compliance risks can impact performance.
2. Competition: Competition from both domestic and international companies could impact Sun Pharma’s market share.

Conclusion

Sun Pharma continues to be a strong candidate for investors looking for growth within the pharmaceutical sector.

With its extensive global reach, emphasis on specialty drugs, and stable financial performance, Sun Pharma is positioned well for long-term growth.

Investors seeking a combination of growth and income through dividends may find Sun Pharma to be a worthwhile addition to their portfolios.